ONCOLOGY

Session presented at ASH 2020.

Drug tested on DLBCL cell lines.

Analysis of data from the UKCCMP registry.

The approval is based on the phase 3 QUAZAR AML-001 trial.

The era of antiretroviral therapy has seen a decline in the incidences of many cancer types in PLWH

VIALE-A study evaluated older patients ineligible for chemotherapy.

Polatuzumab vedotin with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma

The approval was based on DREAMM-2 trial.

Approval based on the DREAMM-2 trial.

Infection is common in patients treated with CD19-directed chimeric antigen receptor T-cell therapy, but it is not associated with higher mortality

The approval is based on the phase 2 L-MIND trial.

The approval is based on the phase 2 L-MIND trial.

Approvals from CHMP's July 2020 meeting.

Avapritinib for GIST and acalabrutinib for CLL were recommended.